CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Free Report) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 27,400 shares, a drop of 24.1% from the February 13th total of 36,100 shares. Based on an average daily trading volume, of 29,400 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.6% of the company’s shares are short sold.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of CASI Pharmaceuticals in a research report on Tuesday, March 11th. They set a “hold” rating for the company.
Read Our Latest Analysis on CASI
CASI Pharmaceuticals Stock Performance
Institutional Trading of CASI Pharmaceuticals
An institutional investor recently raised its position in CASI Pharmaceuticals stock. Woodline Partners LP increased its position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) by 226.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,690 shares of the biotechnology company’s stock after purchasing an additional 69,158 shares during the period. Woodline Partners LP owned approximately 0.64% of CASI Pharmaceuticals worth $282,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.23% of the company’s stock.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Read More
- Five stocks we like better than CASI Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- How to Build the Ultimate Everything ETF Portfolio
- How to Use Stock Screeners to Find Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.